Contract awardedPCR and molecular diagnostic platforms

Invivoscribe supplies PCR master mixes for clonality testing in Wales

Cardiff and Vale University Health Board buys PCR master mixes and reagents from Invivoscribe for B and T cell clonality testing. The All Wales Medical Genomics Service uses the tests to diagnose and monitor blood cancers such as lymphoma. The reagents have to come with validated controls, both clonal and polyclonal, plus a control gene. Invivoscribe also provides technical support.

The contract was awarded directly because changing supplier would mean revalidating and re-accrediting every assay, delaying patient testing. The award was made in December 2025 at £108,316, and the contract runs to December 2026.

Alert me to similar tenders

Contract ends December 2026

What
PCR and molecular diagnostic platforms
Value
£108,316
How it was bought
Direct award
Dates and next
Mar 2026 to Dec 2026

How it was bought

3 official notices
  1. 2 Dec 2025Award noticeFind a Tender
  2. 2 Dec 2025Award noticeFind a Tender
  3. 31 Mar 2026Contract starts
  4. 4 Jun 2026Award noticeFind a Tender
  5. 31 Dec 2026Contract ends

Cardiff and Vale University Health Board has bought this 5 times since 2021

Last bought
Jun 2026
Typical length
3 years
Typical value
£132,573
Suppliers used
4
AwardedContractWon byValue
Jun 2026This purchase9 monthsInvivoscribe technologies SARL£108,316
Feb 2026Locked3 yearsLocked£31,549
Dec 2025Locked3 yearsLocked£132,573
Nov 2025Locked1 yearLocked£736,058
Nov 2025Locked3 yearsLocked£401,048

Suppliers Cardiff and Vale University Health Board has used

SupplierContractsValue
Locked2£432,597
Locked1£736,058
Locked1£132,573
Invivoscribe technologies SARL Won this one1£108,316
See the contracts and who won them

Figures to 21 November 2026

How it compares

With every PCR and molecular diagnostic platforms award since 2021

Half of awards fall between £32,886 and £403,658Median £97,406

Awards
496
Firms that won them
82
Median award
£97,406
of 488 with a value
This award
Bigger than 51%
of them
Typical length
1 year
In Wales
30 awards

Invivoscribe technologies SARL ranks 30th of 82 firms for PCR and molecular diagnostic platforms awards since 2021.

RankFirmAwardsValue
1Locked103£31.8m
2Locked50£13.5m
3Locked45£97m
4Locked33£1.94m
5Locked24£105.1m
5Locked24£1.41m
30Invivoscribe technologies SARL Won this one2£258,316
See who wins this work

PCR and molecular diagnostic platforms at other buyers

Cardiff and Vale University Health Board has awarded 142 contracts since 2021.

See Cardiff and Vale University Health Board's page
  • Invivoscribe technologies SARL has won 2 public contracts since 2021.

2 PCR and molecular diagnostic platforms tenders are open now

See them
More PCR and molecular diagnostic platforms contracts awarded in 2026